PL3325662T3 - Wyciszenie epigenetyczne nmt2 - Google Patents

Wyciszenie epigenetyczne nmt2

Info

Publication number
PL3325662T3
PL3325662T3 PL16826961.1T PL16826961T PL3325662T3 PL 3325662 T3 PL3325662 T3 PL 3325662T3 PL 16826961 T PL16826961 T PL 16826961T PL 3325662 T3 PL3325662 T3 PL 3325662T3
Authority
PL
Poland
Prior art keywords
nmt2
epigenetic silencing
epigenetic
silencing
Prior art date
Application number
PL16826961.1T
Other languages
English (en)
Inventor
Luc G. Berthiaume
Erwan BEAUCHAMP
Original Assignee
Pacylex Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacylex Pharmaceuticals Inc. filed Critical Pacylex Pharmaceuticals Inc.
Publication of PL3325662T3 publication Critical patent/PL3325662T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL16826961.1T 2015-07-17 2016-07-18 Wyciszenie epigenetyczne nmt2 PL3325662T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562194109P 2015-07-17 2015-07-17
PCT/CA2016/050846 WO2017011907A1 (en) 2015-07-17 2016-07-18 Epigenetic silencing of nmt2

Publications (1)

Publication Number Publication Date
PL3325662T3 true PL3325662T3 (pl) 2024-02-26

Family

ID=57833648

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16826961.1T PL3325662T3 (pl) 2015-07-17 2016-07-18 Wyciszenie epigenetyczne nmt2

Country Status (7)

Country Link
US (1) US11788145B2 (pl)
EP (1) EP3325662B1 (pl)
JP (2) JP7539760B2 (pl)
DK (1) DK3325662T3 (pl)
ES (1) ES2964607T3 (pl)
PL (1) PL3325662T3 (pl)
WO (1) WO2017011907A1 (pl)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
PL3325662T3 (pl) * 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2
CN109311858B (zh) 2016-05-26 2021-12-03 里科瑞尔姆Ip控股有限责任公司 Egfr抑制剂化合物
CN110804660B (zh) * 2017-03-06 2022-06-07 新乡医学院 用于检测与结直肠癌长春新碱耐药相关的miRNA表达的引物、试剂盒、方法及应用
CA3066054A1 (en) 2017-06-04 2018-12-13 Rappaport Family Institute For Research In The Medical Sciences Method of predicting personalized response to cancer therapy and kit therefor
US12016900B2 (en) 2017-06-04 2024-06-25 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with an immune checkpoint inhibitor in combination with another therapeutic agent
US12070489B2 (en) 2018-12-12 2024-08-27 Rappaport Family Institute For Research In The Medical Sciences Method of treating cancer with a cancer therapy in combination with another therapeutic agent
WO2019204758A1 (en) * 2018-04-20 2019-10-24 Zhiguo Zhang Compositions and methods for treating glioblastoma by modulating a mgmt enhancer
GB201820660D0 (en) 2018-12-19 2019-01-30 Imperial Innovations Ltd Cancer treatments
GB201820659D0 (en) 2018-12-19 2019-01-30 Imperial Innovations Ltd Novel compostions and their use in therapy
CA3163139A1 (en) * 2018-12-27 2020-07-02 Vivienne I. Rebel Compositions and methods for treating cancer
US12305171B2 (en) 2018-12-27 2025-05-20 Bioaffinity Technologies, Inc. Compositions and methods for treating cancer
US20230255978A1 (en) * 2020-05-12 2023-08-17 Board Of Regents, The University Of Texas System Methods for treating glioblastoma
GB202014736D0 (en) 2020-09-18 2020-11-04 Imperial College Innovations Ltd Novel compounds and their use in therapy
WO2022082306A1 (en) * 2020-10-20 2022-04-28 Pacylex Pharmaceuticals Inc. Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
GB202017367D0 (en) 2020-11-02 2020-12-16 Imperial College Innovations Ltd Novel use
CN112516141A (zh) * 2020-12-07 2021-03-19 浙江大学 Cd47表达抑制剂及其与免疫治疗药物联合使用
JP2024532762A (ja) 2021-08-11 2024-09-10 オンコホスト リミテッド 患者応答の予測
IL314984A (en) * 2022-03-03 2024-10-01 Pacylex Pharmaceuticals Inc Oral PCLX-001 for the treatment of human cancer
TW202421120A (zh) 2022-09-09 2024-06-01 英商邁瑞科艾克斯醫藥有限公司 新穎化合物及其等於治療上之用途
WO2025050208A1 (en) * 2023-09-05 2025-03-13 Pacylex Pharmaceuticals Inc. Oral pclx-001 in the treatment of human cancer
GB202403391D0 (en) 2024-03-08 2024-04-24 Myricx Pharma Ltd Novel compounds and their use in therapy
CN119792264B (zh) * 2025-03-14 2025-06-10 华中科技大学同济医学院附属同济医院 丁酰肼在制备预防或治疗copd的药物中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2657259A1 (fr) 1990-01-25 1991-07-26 Adir Utilisation de la n-myristoyl-(s)-phenylalanine pour l'obtention de medicaments destines au traitement des maladies faisant intervenir la myristoylation.
US20030180292A1 (en) 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US7449464B2 (en) 2003-03-12 2008-11-11 Kudos Pharmaceuticals Limited Phthalazinone derivatives
BRPI0408284B8 (pt) 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
GB0305681D0 (en) 2003-03-12 2003-04-16 Kudos Pharm Ltd Phthalazinone derivatives
GB0317466D0 (en) 2003-07-25 2003-08-27 Univ Sheffield Use
ATE454893T1 (de) 2003-07-25 2010-01-15 Cancer Rec Tech Ltd Tricyclische parp-hemmer
CN1905864B (zh) 2003-12-01 2011-04-06 库多斯药物有限公司 用于治疗癌症的dna损伤修复抑制剂
WO2005053662A1 (en) 2003-12-01 2005-06-16 Kudos Pharmaceuticals Limited Dna damage repair inhibitors for treatment of cancer
EP2394652A3 (en) 2004-02-06 2012-10-24 Elan Pharmaceuticals Inc. Methods and compositions for treating tumors and metastatic disease
PT1771474E (pt) 2004-07-20 2010-05-03 Genentech Inc Inibidores de proteína 4 do tipo angiopoietina, combinações e sua utilização
WO2006086043A2 (en) 2004-11-23 2006-08-17 Science & Technology Corporation @ Unm Molecular technologies for improved risk classification and therapy for acute lymphoblastic leukemia in children and adults
CA2623653C (en) 2005-09-27 2012-08-28 University Of Saskatchewan Use of n-myristoyltransferase on non-tumor tissue for cancer diagnosis
EP2099305B1 (en) 2006-12-18 2015-07-15 Jack L. Arbiser Novel palladium complexes inhibit n-myristoyltransferase activity in vitro and cancer growth in vivo
GB0815947D0 (en) 2008-09-02 2008-10-08 Univ Dundee Compounds
SG10201605814QA (en) 2011-07-22 2016-09-29 Pacylex Pharmaceuticals Inc Synthetic lethality and the treatment of cancer
EP2914261B1 (en) 2012-10-30 2020-12-16 Pacylex Pharmaceuticals Inc. Synthetic lethality and the treatment of cancer
PL3325662T3 (pl) * 2015-07-17 2024-02-26 Pacylex Pharmaceuticals Inc. Wyciszenie epigenetyczne nmt2

Also Published As

Publication number Publication date
JP2022023186A (ja) 2022-02-07
WO2017011907A1 (en) 2017-01-26
US20180208990A1 (en) 2018-07-26
EP3325662A4 (en) 2019-01-02
ES2964607T3 (es) 2024-04-08
EP3325662A1 (en) 2018-05-30
US11788145B2 (en) 2023-10-17
JP2018521654A (ja) 2018-08-09
DK3325662T3 (da) 2023-11-27
EP3325662B1 (en) 2023-08-30
JP7539760B2 (ja) 2024-08-26

Similar Documents

Publication Publication Date Title
PL3325662T3 (pl) Wyciszenie epigenetyczne nmt2
PT3209783T (pt) Silenciamento de genes epigenético permanente
HUE050747T2 (hu) Poggyász
SG11201706729SA (en) Derivatives of sobetirome
SG11201803213XA (en) Glycan-interacting compounds and methods of use
HUE044083T2 (hu) Alvivõk újracstornázása
IL257026A (en) Solid state forms of eluxadoline
GB2536295B (en) Forming of battery components
SG11201707154SA (en) Selective amplification of overlapping amplicons
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
ZA201706282B (en) Solid forms of menaquinols
IL256316A (en) muffler
ZA201708289B (en) Treatment and detection of trypanosomes
IL253773A0 (en) Treatment of dystrophy of the facial, back and arm muscles
GB2556798B (en) Exhaust Diffuser
GB2555051B (en) Exhaust diffuser
ES1137506Y (es) Helice reductora de perdidas
GB201600964D0 (en) Determination of vehicle capabilities
GB2550525B (en) Forming of battery components
FR3039391B1 (fr) Orthese de contention
GB201918494D0 (en) Detection of epigenetic modifications
HUE051526T2 (hu) Izoidid elõállítása és tisztítása
GB201512139D0 (en) Methods of treatment
GB2550742B (en) Determination of density
LU93168B1 (en) Silencing gear